CP and plasma cell myeloma: Bortezomib, which targets both the constitutive proteasome (CP) and the immunoproteasome (IP), is the first clinically approved proteasome inhibitor and is used in the treatment of multiple myeloma and relapsed mantle cell lymphoma (Adams et al, 1999).